Pro Share Advisors LLC Kodiak Sciences Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$5.04 - $9.48 $58,579 - $110,186	-11,623 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$7.09 - $89.45 $21,092 - $266,113	-2,975 Reduced 20.38%	11,623 $90,000
Q4 2021 Feb 08, 2022	SELL	$80.85 - $128.49 $55,463 - $88,144	-686 Reduced 4.49%	14,598 $1.24 Million
Q3 2021 Nov 12, 2021	SELL	$81.97 - $106.94 $214,433 - $279,755	-2,616 Reduced 14.61%	15,284 $1.47 Million
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $160,576 - $263,203	2,080 Added 13.15%	17,900 $1.67 Million
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $94,103 - $140,128	852 Added 5.69%	15,820 $1.79 Million
Q4 2020 Feb 09, 2021	BUY	$60.78 - $154.03 $256,856 - $650,930	4,226 Added 39.34%	14,968 $2.2 Million
Q3 2020 Nov 13, 2020	SELL	$45.05 - $59.27 $12,884 - $16,951	-286 Reduced 2.59%	10,742 $636,000
Q2 2020 Aug 03, 2020	BUY	$42.74 - $66.25 $140,828 - $218,293	3,295 Added 42.61%	11,028 $597,000
Q1 2020 May 15, 2020	SELL	$38.18 - $73.95 $132,751 - $257,124	-3,477 Reduced 31.02%	7,733 $369,000
Q4 2019 Feb 12, 2020	BUY	$13.9 - $76.65 $155,819 - $859,246	11,210 New	11,210 $807,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $392M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.